An unprecedented advance in the fight against pancreatic cancer

José COHEN’s I-BIOT team, in close collaboration with the Institut Curie, has demonstrated for the first time that immunotherapy has a direct impact on pancreatic tumours.

The team has been working for several years on a molecule with great therapeutic potential: the tumour necrosis factor (TNF) type 2 receptor (TNFR2). This molecule, highly expressed by immunosuppressive cells called regulatory T lymphocytes, is a therapeutic target of choice for triggering an anti-leukaemia response in patients relapsing after haematopoietic stem cell transplantation.

A study published in the Journal for Immunotherapy of Cancer, volume 12, number 11, November 2024

More information on the UPEC website